Clinical trial
A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
NCT00050427 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00050427 |
|---|---|
| Title | A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer |
| Official title | A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | PharmaMar Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasms, Neoplasms by Site, Breast Diseases, Skin Diseases |
| Intervention type | Drug |
| Interventions | ET743 |
| Enrollment | 53 |
| Start date | Dec 1, 2002 |
| Completion | Dec 1, 2006 |
| First posted | Dec 18, 2002 |
| Last update posted | Apr 28, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: